Welcome to our dedicated page for Eyenovia news (Ticker: EYEN), a resource for investors and traders seeking the latest updates and insights on Eyenovia stock.
Eyenovia Inc. has changed its corporate name to Hyperion DeFi, Inc. and shifted its public-company updates toward a cryptocurrency treasury reserve strategy centered on HYPE, the native token of the Hyperliquid protocol. Recurring news includes HYPE acquisitions, staking and validator activity, digital-asset treasury governance, and related financing actions.
The company’s legacy ophthalmic technology disclosures continue to reference the Optejet topical ophthalmic medication dispensing platform, including development work on the user-filled device for use with topical ophthalmic liquids. Company updates also cover capital-structure changes, debt amendments, governance matters, and Nasdaq trading under the HYPD symbol following the name change.
Eyenovia (NASDAQ: EYEN) reported its Q1 2024 financial results and updates on key products. The company aims to accelerate the development of MicroPine, a late-stage product for pediatric progressive myopia, and anticipates a 3Q 2024 launch for clobetasol propionate ophthalmic suspension, a new steroid for post-ocular surgery inflammation and pain. Additionally, Eyenovia has trained and shipped products to 50 new Mydcombi-using offices since April 2024.
Financially, the company reported a net loss of $10.9 million or $0.23 per share, compared to a $5.7 million loss or $0.15 per share in Q1 2023. Operating expenses increased by 88.1% year-over-year, partly due to reacquiring MicroPine license rights. Eyenovia reduced anticipated cash-based expenses by $0.8 million per quarter and had $8.0 million in cash and equivalents as of March 31, 2024.
The company has completed manufacturing capabilities with FDA approval for three facilities. A conference call and webcast are scheduled for May 15, 2024, at 4:30 pm ET.
Eyenovia (NASDAQ: EYEN), an ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia, will report its Q1 2024 financial results on May 15, 2024, after the market closes.
A conference call and webcast will follow at 4:30 p.m. ET to review the financial and operating results. Participants can join the call at 1-800-717-1738 (domestic) or 1-646-307-1865 (international). Live and archived webcasts will be available on the investor relations page of Eyenovia's website.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.